Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ivosidenib in the NHS in England.
For the time being, ivosidenib is not recommended for the treatment of adults with locally advanced or metastatic IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments.
